Ancora Advisors, LLC Biomarin Pharmaceutical Inc Transaction History

Ancora Advisors, LLC

$4.06 Billion
Q3 2024

A detailed history of Ancora Advisors, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Ancora Advisors, LLC holds 1,643 shares of BMRN stock, worth $107,879. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,643

Previous 1,793 8.37%

Holding current value

$107,879

Previous $147,000 21.77%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$69.02 - $93.84 $10,353 - $14,076	-150 Reduced 8.37%	1,643 $115,000
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $3,603 - $4,257	43 Added 2.46%	1,793 $156,000
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $11,433 - $14,776	-150 Reduced 7.89%	1,750 $168,000
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $16,186 - $21,726	-200 Reduced 9.52%	1,900 $197,000
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $2,054 - $2,423	-25 Reduced 1.18%	2,100 $178,000
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $6,504 - $7,903	-91 Reduced 4.11%	2,125 $176,000
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $159,033 - $198,449	2,141 Added 2854.67%	2,216 $171,000
Q1 2022 May 13, 2022	SELL	$74.28 - $92.69 $168,318 - $210,035	-2,266 Reduced 96.8%	75 $6,000
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $137,415 - $175,256	1,916 Added 450.82%	2,341 $207,000
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $26,169 - $29,914	350 Added 466.67%	425 $33,000
Q4 2020 Feb 12, 2021	SELL	$72.61 - $90.2 $14,522 - $18,040	-200 Reduced 72.73%	75 $7,000
Q1 2020 May 14, 2020	BUY	$71.37 - $96.85 $19,626 - $26,633	275 New	275 $23,000

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.2B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ancora Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ancora Advisors, LLC with notifications on news.

Account

Ancora Advisors, LLC Biomarin Pharmaceutical Inc Transaction History